<DOC>
	<DOCNO>NCT02878616</DOCNO>
	<brief_summary>Investigate whether concomitant treatment intravenous immunoglobulin ( IVIG ) alter pharmacokinetics pharmacodynamics LFG316 extent would necessitate dose adaptation LFG316 pre-sensitized end-stage renal disease patient await kidney transplantation</brief_summary>
	<brief_title>Study End-stage Renal Disease Patients Awaiting Kidney Transplant Investigate Potential Effect IVIG Treatment Pharmacokinetics Pharmacodynamics LFG316</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<criteria>1 . Adult men woman 1870 year age suffering endstage renal disease chronic dialysis therapy . 2 . Candidates kidney transplantation presensitized undergoing desensitization therapy . 3 . Written informed consent must obtain assessment perform . 4 . Able communicate well investigator , understand comply requirement study . 5 . Recipients ABO compatible donor allograft . 6 . Patients await kidney allograft living decease donor . For patient await transplant living donor , kidney transplantation must occur 28 day postLFG316 infusion . 7 . History vaccination meningococcus pneumococcus 2 week 36 month prior dose . Documentation require . If patient vaccinate , must vaccinate least 2 week prior dose . The choice vaccine ( ) take account serotypes prevalent geographic area study patient enrol . 1 . Patients require undergoing peritoneal dialysis . 2 . Patients know contraindication treatment blood product . 3 . Patients know prothrombotic disorder and/or history thrombosis hypercoagulable state , exclude hemodialysis venous access clot . 4 . Patients positive PCR result hepatitis B and/or hepatitis C , and/or history immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . 5 . Patients risk tuberculosis ( TB ) 6 . Patients severe , progressive uncontrolled acute chronic medical condition relate endstage renal disease ( uncontrolled infectious disease sepsis ) , clinical laboratory abnormality screen baseline investigator 's opinion would make patient inappropriate entry study , know active presence malignancy . 7 . Pregnant nursing ( lactate ) woman . 8 . Women childbearing potential , unless highly effective method contraception use dose 50 day last dose LFG316 , sexually active male unwilling use condom intercourse take investigational drug 50 day last dose LFG316 . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>